[Radiotherapy of the prostate gland--old wine in a new bottle?].
The outcome and morbidity in the treatment of prostate cancer by radiation therapy depends on the balance between tumour control and normal tissue damage. Recent technological advances have allowed to reduce the amount of normal tissue included in target treatment volumes. This diminishes morbidity and provides an opportunity for dose escalation, increasing tumour control rates. The new application techniques are discussed along with their integration in treatment concepts. Although there are no randomised studies to provide evidence of increased survival, the available evidence supports the hypothesis that the introduction of novel radiation techniques leads to survival rates equivalent to surgical series with sufficient safety.
Aebersold
D M
DM
Klinik und Poliklinik für Radio-Onkologie, Universität Bern, Inselspital. daniel.aebersold@insel.ch
D006801:Humans; D008297:Male; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians' / Q000639:trends; D011471:Prostatic Neoplasms / Q000401:mortality / Q000532:radiotherapy*; D011832:Radiation Injuries / Q000517:prevention & control*; D011878:Radiotherapy / Q000009:adverse effects / Q000295:instrumentation / Q000379:methods* / Q000639:trends; D011880:Radiotherapy Planning, Computer-Assisted / Q000379:methods* / Q000639:trends; D011881:Radiotherapy, Computer-Assisted / Q000379:methods* / Q000639:trends; D016896:Treatment Outcome